Bifogade filer
PDF
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Mid Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
June 4, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") entered into a conditional agreement on May 20, 2024 to acquire all shares in Flerie Invest AB ("Flerie") (the "Transaction"). In the acquisition, Flerie is valued at approximately SEK 3,073 million, representing a discount of approx. 15.7 percent compared to the Net Asset Value (NAV) above as of May 31, 2024. The acquisition takes place through a non-cash issue of shares in InDex Pharmaceuticals, meaning that each share in Flerie will correspond to approx. 54 newly issued shares in InDex Pharmaceuticals. The stated NAV per share in Flerie thus corresponds to approximately SEK 0.60 per share in InDex Pharmaceuticals.
Background
On May 20, 2024, InDex Pharmaceuticals entered into an agreement to acquire all shares in Flerie through an issue in kind. The Transaction constitutes a so-called reverse merger whereby Flerie becomes a wholly owned subsidiary of InDex Pharmaceuticals. Flerie's shareholders will initially hold approximately 91.9 percent of the total number of shares and votes in the Company, prior to the completion of the capital raising described in the press release published by the Company on May 20, 2024. The completion of the reverse merger is conditional upon resolutions at extraordinary general meetings to be held on June 10, 2024 and that the Company receives approval for continued listing on Nasdaq First North Growth Market
Fleries NAV per May 31, 2024
In light of the above, the Company today publishes Flerie's NAV. On May 31, 2024 Flerie's NAV per share was SEK 32.37. The information in the table supplements the information presented in the corresponding table in the section `Business description - Flerie Invest's portfolio' on page 38 of the company description published by InDex Pharmaceuticals on May 27, 2024.
Allocation of net Share of Fair Part of NAV Share of NAV
asset value portfolio value per share
company (MSEK) (SEK)
Product Development
Prokarium 42% 470 4.17 12.9%
Xspray Pharma 17% 426 3.79 11.7%
Empros Pharma 79% 204 1.82 5.6%
KAHR Medical 31% 199 1.77 5.5%
Atrogi 34% 154 1.37 4.2%
Microbiotica 11% 134 1.19 3.7%
Lipum 57% 126 1.12 3.5%
Mendus 24% 119 1.06 3.3%
Geneos Therapeutics 12% 101 0.90 2.8%
Toleranzia 58% 88 0.78 2.4%
Xintela 56% 85 0.76 2.3%
Egetis Therapeutics 2% 59 0.52 1.6%
Vitara Biomedical 5% 56 0.50 1.5%
Synerkine Pharma 43% 52 0.47 1.4%
AnaCardio 19% 52 0.46 1.4%
Buzzard 15% 29 0.26 0.8%
Pharmaceuticals
Sixera Pharma 23% 26 0.23 0.7%
Alder Therapeutics 21% 17 0.15 0.5%
Amarna Therapeutics 60% 12 0.10 0.3%
Strike Pharma 14% 6 0.05 0.2%
EpiEndo 10% 0 0.00 0.0%
Pharmaceuticals
Total 2,414 21.45 66.2%
Commercial Growth
NorthX Biologics 92% 189 1.68 5.2%
Symcel 31% 169 1.50 4.6%
Nanologica 39% 104 0.93 2.9%
A3P Biomedical 8% 75 0.67 2.1 %
Provell 72% 65 0.58 1.8%
Pharmaceuticals*
Chromafora 34% 53 0.47 1.4%
Frontier Biosolutions 2% 19 0.17 0.5%
Bohus Biotech 45% 17 0.15 0.5%
Total 691 6.14 19.0%
Limited Partnerships, 77 0.68 2.1%
total
Assets related to 372 3.31 10.2%
Portfolio companies
Other assets and 90 0.80 2.5%
liabilities
Net asset value 3,644 32.37 100.0%
* indirect shares in
Provell
Pharmaceuticals
For more information:
Jenny Sundqvist, CEO
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, CFO and deputy CEO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indxpharma.com
Ted Fjällman, CEO of Flerie
E-mail: contact@flerie.com
Publication
This information is information that InDex Pharmaceuticals Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (MAR). The information was submitted for publication through the agency of the contact person set out above at 08.55 CEST on June 4, 2024.
InDex Pharmaceuticals in brief
InDex Pharmaceuticals is based in Stockholm, Sweden. The Company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the Company's Certified Adviser. For more information, please visit www.indexpharma.com.